Seeking Alpha

Heart specialists frown on hypertension-lowering device

  • Some leading U.S. and European cardiologists favor curbs on sales or an outright moratorium on renal denervation devices.
  • After Medtronic's (MDT +0.7%Simplicity clinical trial failed to meet its efficacy endpoint doctors question the continued use of the product to treat high blood pressure in patients who fail to gain enough of a benefit from drugs.
  • The therapy is currently approved in more than 80 countries. Analysts believe the U.S. market would be $3B if and when the FDA approves a device for the indication.
  • The renal denervation procedure uses a catheter to insert the device through the groin and into the kidney where it applies RF pulses to the renal arteries to damage the nerve endings in the vascular wall. Physicians believe these nerves contribute to elevated blood pressure.
  • (BSX) (STJ)
From other sites
Comments (1)
  • khaz
    , contributor
    Comments (88) | Send Message
     
    And do those leading cardiologists cash checks from big pharma?
    9 Apr, 07:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector